Emergent BioSolutions
NEWS
Continuing studies and news about COVID-19 around the world keeps coming in. Here’s a look.
Emergent said the vaccine candidate against the mosquito-borne illness showed an increase in immune response as measured by anti-chikungunya virus SNA.
The House Select Subcommittee on the Coronavirus Crisis questioned executives from Emergent BioSolutions as part of a congressional probe.
Emergent company executives Fuad El-ibri and Robert Kramer will be testifying before a congressional probe after a botched batch of 15 million doses of J&J’s COVID-19 vaccine.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 4, 2021.
Battered by vaccine manufacturing mishaps that led to the contamination of 15 million doses of the Johnson & Johnson vaccine, Emergent BioSolutions is shaking up its leadership to ensure such errors do not occur again.
The U.S. FDA has requested that Emergent BioSolutions temporarily pause production of ingredients for the Johnson & Johnson COVID-19 vaccine at their facility in Baltimore.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 6, 2021.
In order to have full control of J&J’s product, the production of the AstraZeneca vaccine, which was being conducted at the same facility, will move elsewhere.
JOBS
IN THE PRESS